NEXTHINK
28.10.2015 08:31:45 CET | Business Wire | Press release
Nexthink®, a pioneer and leader in end-user centric IT Operations Analytics (ITOA), today announced a partnership with Ymor , a leading APM service provider in the Netherlands. Under the agreement, Ymor will be able to provide consulting services, support and implement Nexthink’s IT analytics solutions for its customers.
Ymor unburdens customers through its Ketenbewaking™ service portfolio that protects and optimizes the IT environment by focusing on end-users. By integrating Nexthink’s technology into its offering, Ymor is able to expand and enhance its existing services. In addition to technical, configuration, end-to-end and component monitoring, Ymor can now offer its customers workspace monitoring. Nexthink’s visibility and IT analytics allow Ymor to provide control over the workspace that can lead to fast ROI and financial savings.
"As we strive for ‘end-user happiness,’ workplace monitoring is more important than ever before,” said Martin van den Berge, Director Ymor . “Throughout the workday, most end-users spend at least 5 hours using various applications. Performance issues cause frustration and lead to decreased efficiency for both end-users and the business. Working with Nexthink provides us with an opportunity to measure the end-user experience, to obtain a ‘helicopter view’ of the IT infrastructure, to quickly and easily find the root cause of issues and to achieve the goal of happy end-users.”
Ymor and Nexthink have implemented workplace monitoring with the city of The Hague. Gerard van Lieshout, Sr. Corporate IT Advisor of The Hague : “We use Nexthink to monitor all enterprise desktops, some 7,000 workspaces. By measuring delays, crashes and bottlenecks directly on the desktops, it gives us a better understanding on how our employees use the desktops. This not only allows us to respond better to reported incidents, but also to adjust configurations of the desktops before problems occur.”
“We are excited about the partnership with Ymor and extending our reach in Northern Europe,” said Nathan Wyld, Europe Channel Director at Nexthink . “As a result of this partnership, organisations in the Netherlands can benefit from Nexthink’s IT analytics and Ymor’s outstanding services and support for implementation and optimal use of IT analytics in their environments.”
###
About Ymor:
Ymor is a fast growing and innovative service provider based in Utrecht, which assists the Dutch Top 500 companies in improving the performance of complex IT environments with the goal of unburdening end-users. An organisation may be experiencing problems with performance or availability. It may be building a new application or wish to bring it online. Or there may simply be a need for the complex IT chain to be closely monitored. In all such cases the Ymor ‘Ketenbewaking’ service monitors and optimises the IT environment. Our slogan says it all: “Ymor creates user happiness!”
View source version on businesswire.com: http://www.businesswire.com/news/home/20151028005061/en/
./ContentItem/FormatNexthink and Ymor partnership to meet demand for IT Analytics solutions in the Netherlands and significant customer win: city of The Hague
Contact:
Media contacts:
Nexthink
Victoria Calmon, +33 6
34 77 15 97
victoria.calmon@nexthink.com
www.nexthink.com
or
Ymor
Inge
Vollebregt, +31 610762591
ivollebregt@ymor.nl
www.ymor.nl
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
